Top

Published in:

01-01-2003 | Adis R&D Profile

Trabectedin

ET 743, Ecteinascidin 743, Yondelis

Published in: Drugs in R&D | Issue 1/2003

Excerpt

Trabectedin [Ecteinascidin 743, Yondelis, ET 743, NSC 684766] is one of a series of compounds isolated from the Caribbean tunicate, Ecteinascidia turbinata.¹ It interacts with the minor groove of DNA and alkylates guanine at the N2 position. In this manner, it is thought that trabectedin may affect various transcription factors involved in cell proliferation. Trabectedin blocks the G2 phase of the cell cycle while cells in G1 are most sensitive to the drug. It also inhibits the overexpression of the multidrug resistance-1 gene (MDR-1) coding for the P-glycoprotein, a major factor responsible for cells developing resistance to cancer drugs. …

This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

Jimeno J, Villalona-Calero M, Eckhardt G, et al. Phase I and pharmacokinetic study of ET-743, a novel minor groove binder of marine origin on a daily x 5 schedule. 34th Annual Meeting of the American Society of Clinical Oncology 17: 191, 16 May 1998

Hillebrand MJX, Jimeno J, Bowman A, et al. Pharmacokinetics of Ecteinascidin-743 in three phase I studies. Annals of Oncology 9 (Suppl 2): 119, 1998

Taamma A, Riofrio M, Beijnen JH, et al. Ecteinascidin-743 24 hour continuous intravenous infusion phase I study in solid tumors patients. 89th Annual Meeting of the American Association for Cancer Research 323, 28 Mar 1998

Beijen JH, Rosing H, Cvitkovic E, et al. Pharmacokinetics and pharmacodynamics of ET-743 (ecteinascidin-743) in phase I trials. 35th Annual Meeting of the American Society of Clinical Oncology 18: 163, 15 May 1999

Twelves C, Hoeckman H, Bowman A, Beijnen JH, Faber JH, et al. A phase I and pharmacokinetic study of ET-743 evaluating a 3 hours intravenous infusion in patients with solid tumors. Clinical Cancer Research. 5 (Suppl): 3790–3791, Nov 1999. ECSG/EORTC, Glasgow, UK; PharmaMar, Madrid, Spain

Twelves CJ, Vermorken J, Bowman A, Early Clinical Studies Group of the EORTC, et al. Phase I and pharmacokinetic study of ecteinascidin-743 (ET-743) given as a one hour infusion every 21 days. European Journal of Cancer Part A. 33 (Suppl 8): 245, Sep 1997CrossRef

Bowman A, Twelves C, Hoekman K, et al. Phase I clinical and pharmacokinetic study of ecteinascidin-743 given as a one hour infusion every 21 days. Annals of Oncology 9 (Suppl 2): 118, 1998

Delaloge S, Riofrio M, Brain E, Cottu P, Taamma A, et al. Ecteinascidin in heavily pretreated refractory sarcomas: preliminary evidence of activity. European Journal of Cancer 35 (Suppl 4): 271 (plus poster), Sep 1999CrossRef

Zelek L, Yovine A, Brain E, Jimeno J, Taamma A, et al. Ecteinascidin-743 in taxane/anthracycline pretreated advanced/ metastatic breast cancer patients: preliminary results with the 24 hour continuous infusion Q3week schedule. 36th Annual Meeting of the American Society of Clinical Oncology 19: 149, 20 May 2000

10.

Le Cesne A, Blay J, Judson I, Van Oosterom A, Verweij J, et al. ET-743 is an active drug in adult soft-tissue sarcoma: a STBSG-EORTC phase II trial. 37th Annual Meeting of the American Society of Clinical Oncology. 20: 353, Part 1, 12 May 2001

11.

Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. European Journal of Cancer 37: 97–105, Jan 2001PubMedCrossRef

12.

Takebayashi Y, Goldwasser F, Urasaki Y, Kohlhagen G, Pommier Y. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clinical Cancer Research 7: 185–191, Jan 2001PubMed

13.

Hendriks HR, Fiebig HH, Giavazzi R, et al. ET743, a marine natural product with high antitumour activity in human tumor xenograft models. Annals of Oncology 7 (Suppl 1): 33, 1996

14.

Valoti G, Nicoletti MI, Pellegrino A, et al. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clinical Cancer Research 4: 1977–1983, Aug 1998PubMed

15.

Ghielmini M, Colli E, Erba E, et al. In vitro cytotoxicity of Ecteinascidin 743 against human hemopoietic progenitors and cancer cells. Annals of Oncology 9 (Suppl 2): 139, 1998

16.

Ghielmini M, Colli E, Erba E, et al. In vitro schedule-dependency of myelotoxicity and cytotoxicity of ecteinascidin 743 (ET-743). Annals of Oncology 9: 989–993, Sep 1998PubMedCrossRef

17.

Erba E, Bergamaschi D, Ronzoni S, et al. Mode of action of Ecteinascidin 743, a natural marine compound with antitumoral activity. Annals of Oncology 9 (Suppl 2): 139, 1998

18.

Izbicka E, Lawrence R, Davidson K, et al. Incomplete crossresistance between Ecteinascidin-743 and standard chemotherapeutic agents against primary tumors in human tumor cloning assay. Annals of Oncology 9 (Suppl 2): 34, 1998

19.

Izbicka E, Lawrence R, Raymond E, et al. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Annals of Oncology 9: 981–987, Sep 1998PubMedCrossRef

20.

Gorfajn BD, Jin S, Hu Z, Scotto KW. ET743, a novel transcription- targeted cehmotherapeutic that inhibits activation of the MDR1 promoter by multiple inducers. 91st Annual Meeting of the American Association for Cancer Research 41: 804, Mar 2000. Memorial Sloan-Kettering Cancer Center, New York, New York, USA

21.

PharmaMar. Aplidin (APL) and Yondelis (ET-743), PharmaMar’s two lead anti-tumour agents, show encouraging results. Media Release: 23 Oct 2002. Available from URL: http://www.pharmamar.es

22.

Taamma A, Misset JL, Delaloge S, Guzman C, Di Palma M, et al. Ecteinascidin-743 in heavily pretreated refractory sarcomas: early results of the French experience. Clinical Cancer Research 5 (Suppl): 3791, Nov 1999

23.

PharmaMar. Drug derived from marine organisms continues to show favorable results in cancer trials. Media Release: [2 pages], 23 May 2000. Available from URL: http://www.pharmamar.com

24.

Demetri GD, Seiden M, Garcia-Carbonero R, Supko J, Harmon D, et al. Ecteinascidin (ET-743) shows promising activity in distinct populations of sarcoma patients: summary of 3 U.S.- based phase II trials. 36th Annual Meeting of the American Society of Clinical Oncology. 19: 553, 20 May 2000

25.

Demetri G, Garcia-Carbonero R, Harmon D, Seiden M, Jimeno J, et al. Ecteinascidin-743 induces objective responses and disease control in patients with advanced non-osseous sarcomas: results from phase II trials. Annals of Oncology 11 (Suppl 4): 126, 2000

26.

Le Cesne A, Judson I, Radford J, Blay J-Y, Van Oosterom A, et al. Phase II study of ET-743 in advanced soft-tissue sarcoma (ASTS) in adult: a STBSG-EORTC trial. Annals of Oncology. 11 (Suppl 4): 126, 2000

27.

PharmaMar. Marine-derived ET-743 may increase survival for cancer patients — promising development in treatment of sarcoma. Media Release: [4 pages], 14 May 2001. Available from URL: http://www.pharmamar.com

28.

PharmaMar. PharmaMar reinforces company commitment to improving cancer care by holding a satellite symposium on soft tissue sarcoma (STS) and the clinical benefits of Yondelis (ET-743). Media Release: 22 Oct 2002. Available from URL: http://www.pharmamar.com

Title: Trabectedin
ET 743, Ecteinascidin 743, Yondelis
Publication date: 01-01-2003
Publisher: Springer International Publishing
Published in: Drugs in R&D / Issue 1/2003
Print ISSN: 1174-5886
Electronic ISSN: 1179-6901
DOI: https://doi.org/10.2165/00126839-200304010-00016

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Trabectedin

ET 743, Ecteinascidin 743, Yondelis

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2003

Morphine/Dextromethorphan — Endo

Immunosuppressive and Anti-Inflammatory Mechanisms of Triptolide, the Principal Active Diterpenoid from the Chinese Medicinal Herb Tripterygium wilfordii Hook. f.

Talaporfin

Emtricitabine

Effect of Policosanol on Carbon Tetrachloride-Induced Acute Liver Damage in Sprague-Dawley Rats

Efficacy of Rebamipide as Adjunctive Therapy in the Treatment of Recurrent Oral Aphthous Ulcers in Patients with Behçet’s Disease